{
    "clinical_study": {
        "@rank": "111022", 
        "arm_group": [
            {
                "arm_group_label": "FX006 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "FX006 10 mg, single IA injection"
            }, 
            {
                "arm_group_label": "FX006 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "FX006 40 mg single IA injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be an open-label, single administration design, conducted in  patients with\n      OA of the knee.\n\n      Patients will be enrolled sequentially with 8 to 10 patients per Cohort as follows:\n\n      Cohort A: FX006 40mg, Final Visit at Week 20 Cohort B: FX006 40 mg, Final Visit at Week 16\n      Cohort C: FX006 10 mg, Final Visit at Week 12 Cohort D: FX006 40 mg, Final Visit at Week 12\n\n      Each patient will be evaluated for up to 12, 16 or 20 weeks following a single\n      intra-articular (IA) injection of FX006 at 10 mg or 40 mg, depending on the assigned Cohort.\n       Following the screening visit, safety will be evaluated at three (3) out-patient visits and\n      synovial fluid will be collected at Day 1 for baseline measurements and the Final Visit for\n      drug concentration measurements."
        }, 
        "brief_title": "Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osetoarthritis of the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Written consent to participate in the study\n\n          -  Willingness and ability to comply with the study procedures and visit schedules and\n             ability to follow verbal and written instructions\n\n          -  Has documented diagnosis of OA of the index knee made at least 6 months prior to\n             Screening\n\n          -  Currently meets American Collage of Rheumatology Criteria (clinical and radiological)\n             for OA\n\n          -  Index knee pain for >15 days over the last month\n\n          -  Body mass index (BMI) \u2264 40 kg/m2\n\n          -  Ambulatory and in good general health\n\n        Key Exclusion Criteria:\n\n          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing\n             spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or\n             amyloidosis\n\n          -  History of arthritides due to crystals (e.g., gout, pseudogout)\n\n          -  History of infection in the index joint\n\n          -  Clinical signs and symptoms of active knee infection or crystal disease of the index\n             knee\n\n          -  Presence of surgical hardware or other foreign body in the index knee\n\n          -  Unstable joint (such as a torn anterior cruciate ligament) within 12 months of\n             Screening\n\n          -  IA corticosteroid (investigational or marketed) in any joint within 6 months of\n             Screening\n\n          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of\n             Screening\n\n          -  Oral corticosteroids (investigational or marketed) within 1 month of Screening\n\n          -  Inhaled, intranasal and topical corticosteroids (investigational or marketed) within\n             2 weeks of Screening\n\n          -  Any other IA investigational drug/biologic within 6 months of Screening\n\n          -  Prior use of FX006\n\n          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening\n\n          -  Planned/anticipated surgery of the index knee during the study period\n\n          -  Active or history of malignancy within the last 5 years, with the exception of\n             resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected\n             cervical atypia or carcinoma in situ"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003365", 
            "org_study_id": "FX006-2013-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "FX006 10 mg", 
                "intervention_name": "FX006 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FX006 40 mg", 
                "intervention_name": "FX006 40 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Triamcinolone hexacetonide", 
                "Triamcinolone", 
                "Triamcinolone Acetonide", 
                "Triamcinolone diacetate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "osteoarthritis", 
            "knee", 
            "steroids", 
            "FX006", 
            "triamcinolone acetonide", 
            "synovial fluid"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paducah", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ducansville", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measure the concentration of triamcinolone acetonide in synovial fluid", 
            "safety_issue": "No", 
            "time_frame": "12 to 20 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003365"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of treatment emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 to 20 weeks"
        }, 
        "source": "Flexion Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Flexion Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}